In this issue investigators (Aliu et al, 2020) showed that poly(phenyl disodium 3‐O‐sulfo‐β‐d‐glucopyranuronate)‐(1→3)‐β‐d‐galactopyranoside, known as PPSGG, removed anti‐MAG IgM autoantibodies from the blood in a mouse model of this IgM neuropathy. In a previous study these investigators developed antigen‐specific molecules with nanomolar inhibitory potency for anti‐MAG IgM (Herrendorff et al., 2017). Here the investigators also show that PPSGG blocked the binding of an anti‐MAG IgM from patients to sciatic nerve myelin of non‐human primates. They also tested some of the pharmacokinetic and pharmacodynamic properties of PPSGG.